Open Access<p>The Cost-Effectiveness of Universal Varicella Vaccination in Italy: A Model-Based Assessment of Vaccination Strategies</p>
Author(s) -
Chiara Azzari,
Vincenzo Baldo,
Sandro Giuffrida,
Ray Gani,
Elliott O'Brien,
C Alimenti,
Vincent Daniels,
Lara J. Wolfson
Publication year - 2020
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s229685
Subject(s) - medicine , vaccination , varicella vaccine , rubella , measles , cost effectiveness , chickenpox vaccine , pediatrics , virology , rubella vaccine , chickenpox , immunization , immunology , virus , immune system , risk analysis (engineering)
In 2017, varicella vaccination became mandatory for all children in Italy, based on a two-dose schedule administered at 12-15 months of age and 5 to 6 years of age. Varicella vaccines are available in different formulations (as a single vaccine or as a combination vaccine together with measles, mumps, and rubella) and are made by multiple manufacturers with different effectiveness profiles. This study calculates the cost-effectiveness of a range of varicella vaccination strategies to identify the optimal strategy for Italy.